Our Latest Book on Curcumin is a Comprehensive Review of its Enormous Clinical Power

We feel privileged being pioneers in bringing in the plentiful and beneficial health-promoting benefits of Curcuma longa (commonly known as ‘turmeric’)―the golden spice originating from the Indian subcontinent, in the form of Curcumin C3 Complex®, a highly-celebrated phytoextract in the nutraceutical and dietary supplement marketplace today.

Not just that. We have always strived to inform, educate and create awareness to our loyal customers about true quality of this nature - made wonder molecule and its powerful inherent multi - therapeutic properties. And through the book titled —“Curry Powder to Clinical Significance” once again we want to share the knowledge about ever-evolving, enormous clinical power of this nature-derived pharma cocrystal called Curcumin C3 Complex® with all our beloved customers and health enthusiasts.

This book, we believe, is “the most-awaited testimony” of curcumin, in turn curcuminoids, as it is a compilation of most credible set of curcumin data, which includes more than 80 research papers, including 45+ clinical studies on Curcumin C3 Complex® published in peer-reviewed journals and still counting...!

We also firmly believe that this book would help people from different quarters, viz. researchers, formulators and consumers in making the correct choice, and thrust aside unsubstantiated so-called bioavailable curcumin and/or synthetic versions, and experience natural health benefits of this wonderful “Bioprotectant.”

Have a happy and healthy reading...!

Book your copy at www.Amazon.com today...!

About Author

Muhammed Majeed, Ph.D.

Dr. Muhammed Majeed holds a doctorate (1986) in Industrial Pharmacy from St. John’s University, New York. He has over 15 years of pharmaceutical research experience in the United States with leading companies such as Pfizer Inc., Carter-Wallace and Paco Research.

Subsequent to the formation of his company, Sabinsa Corporation in 1988, he has pursued his interest in phytochemistry and pharmaceutical sciences. He has led a team of scientists, both in India & USA, and obtained 115 US and International patents so far. He is aggressively pursuing his interest in natural products and continues to develop new products for the US and International markets.


Effects of curcumin on Helicobacter pylori infection


Ann Transl Med2016;4(24):479


Around the world, more than 50% people are believed to be infected with Helicobacter pylori, a Gram-negative bacterium, which selectively colonizes the human gastric epithelium and is associated with stomach and colorectal cancer, as well as gastritis and peptic ulcer etiology. Genetic variability and its capacity to build biofilm are thought to be the reason why this bacterium is resistant to common antibiotics.

As a result, several researchers have been looking out for natural products with possible antibacterial potential as an alternative, for example curcumin. Several studies have suggested that curcumin inhibits H. pylori infection via multiple roles. 



To compare the antibacterial effects of five different formulations of curcumin.


Study Design:

  • In this study, various parameters were evaluated to determine anti-inflammatory and anti-infective activity and immunostimulating properties of different samples of curcumin, in addition to their role against oxidative damage, H. pylori-induced gastritis
  • Following curcumin samples were used in the study:
    • Sample #1:  Curcumin C3 complex 95% (purchased from Sabinsa Corp., East Windsor, NJ, USA)
    • Sample #2:  Curcumin powder 65% (from Sigma, St. Louis, MO, USA)
    • Sample #3:  Curcumin 94% (from Sigma, St. Louis, MO, USA)
    • Sample #4:  Curcumin 95 (from Jarrow Formulas, Los Angeles, CA, USA), and
    • Sample #5:  Curcumin 95% (from Orcas Naturals, Landing, NJ, USA)


Results and Discussion:

  • Data suggested all samples except sample #4 showing significantly enhanced serum levels of IL-4, an anti-inflammatory cytokine, with Curcumin C3 Complex® (i.e. sample #1) being more potent
  • Similarly, sample #1 showed highest inhibition of IFN-γ levels (elevated by H. pylori infection) compared to other samples (Fig. 1)
  • Inhibition of somatostatin and gastrin levels was highest with sample #1
  • Except sample #4, all curcumin samples showed antioxidant efficacy, as suggested by decreased LPO levels, a marker of oxidative membrane damage. Similar results were seen with MPO levels, a pro-inflammatory marker
  • Curcumin supplementation was able to decrease total amount and growth of H. pylori bacteria when stomach of infected animals was evaluated. Sample #1 was found to be more potent
  • Determination of role of curcumin supplementation on formation of anti-H. pylori IgG antibodies revealed that sample #1, #3 and #5 having strongest effects―suggesting strong immunostimulating properties (Fig. 2)



Overall, curcumin can reduce effects of H. pylori infection. However, activity varies between different curcumin samples, despite the clear activity of curcumin in general. Curcumin C3 Complex® (sample #1) was found to be the most active of all samples in all of tests conducted.


By using this Site, you agree to the terms and conditions which constitute the entire agreement between Sabinsa Corporation and you. These Terms supersede all prior and contemporaneous representations, warranties and understandings, whether oral or written with respect to the Site, its contents and any services provided on the site. In the event of any conflict between these Terms and any agreement or understanding related to the Site, the Terms shall control.

Material on this website is protected under the copyright law and is the property of the Sabinsa Corporation. All rights in this material are reserved. The information and images presented here may not under any circumstances be reproduced or used without prior written permission. Users may view and download material from this site only for personal, non-commercial home use. Any act to reproduce, republish, upload, post, transmit, distribute or publicly display material from this website without the written permission of Sabinsa Corporation will constitute an infringement of the Copyright.

Users agree not to use the site for sale, trade or other commercial purposes. Users may not use language that is threatening, abusive, vulgar, discourteous or criminal. Users also may not post or transmit information or materials that would violate rights of any third party or which contains a virus or other harmful component. Sabinsa Corporation reserves the right to remove or edit any messages or material submitted by users.

The User understands and acknowledges that any links which takes the User to third party sites is not maintained by Sabinsa Corporation and Sabinsa Corporation’s privacy policy does not apply. This link is provided to you for convenience and does not serve as an endorsement by Sabinsa Corporation of any information or contacts that you may find on this non-Sabinsa Corporation site.

Under no circumstances, including but not limited to negligence, will Sabinsa Corporation be liable for special or consequential damages that result from the use or inability to use the materials in this site.

This agreement is effective until terminated by either party. You may terminate this agreement at any time by discontinuing your use of this site and destroying all materials obtained from it.

By using this Site you agree that these terms shall be governed by and construed in accordance with the laws of the jurisdiction of the State of New Jersey, USA, without regard to its conflict of laws rules. By using this Site you also agree that any litigation arising out of or in connection with these Terms shall be brought in the courts of New Jersey jurisdiction.


These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq

Biochem Pharmacol.2017;135:22–34.


Chronic inflammation is known to play a significant role in the development of pathogenesis of tumors in multiple human cancers, including colorectal cancer (CRC), the fourth leading cause of cancer-related deaths worldwide. In the US alone, CRC is estimated to account for more than 49,190 deaths in 2016. Colitis-accelerated colon cancer (CAC), a subtype of CRC, is closely associated with inflammatory bowel disease (IBD).

In recent years, though therapeutic options, such as surgery, radiation therapy, chemotherapy, and targeted therapy for CRC treatment have been effective, most of these strategies suffer from various side effects. Aspirin has been found to be an effective agent in lowering the risk of different types of CRC. However, its use has been limited owing to the potential side effects of gastrointestinal bleeding at high-dose. Co-administration of two or more low-dose chemopreventive agents with different molecular mechanisms may be a promising strategy to maximize efficacies and minimize toxicities.

Curcumin, the principal costituent of turmeric, is another widely studied chemopreventive candidate for CRC and has shown promising effects in suppressing inflammation and colon cancer cell growth. Several studies have also demonstrated that both aspirin and curcumin are multi-target chemopreventive agents that modulate various signaling pathways and molecules involved in inflammation, tumor initiation, and tumor progression.



To determine the effect of aspirin, curcumin and their combination in azoxymethane/dextran sulfate sodium
(AOM/DSS) - induced colitis-accelerated colorectal cancer (CAC).


Study Design:

Six-week-old mice were injected with AOM (10 mg/kg) to induce colitis. After a week, the drinking water for the mice injected with AOM was replaced with DSS (1.2% w/v) for 7 days. During DSS administration period, symptoms of acute colitis were monitored by calculating the disease activity index (DAI) daily. Mice were fed with diets supplemented with 0.02% aspirin, 2% curcumin, or 0.01% aspirin + 1% curcumin from 1 week prior to the AOM injection until the experiment was terminated (i.e. 22 weeks after AOM initiation). During the experiment period, body weight and the consumption of food and fluid were recorded every week. At the end of the experiment colons were examined for the tumors as well as used for histological analysis.



  • Data suggested that tumor inhibitory efficacy of curcumin was superior to that of aspirin; while their combination at a lower dose produced similar efficacy when compared to that of a higher dose of curcumin at 2%
  • RNA-seq analysis showed that low-dose combination of aspirin and curcumin modulated larger gene sets that are known to play important role in the inflammatory network and liver metastasis in CAC
  • A small subset of genes were also identified, which may be potential molecular targets of the combination of aspirin and curcumin in preventing CAC



Overall, co-administration of low-dose combination of aspirin and curcumin produced chemopreventive effects against CAC. Furthermore, the transcriptional profile obtained in this study may be helpful in identifying underlying mechanism of the carcinogenesis process of inflammatory CRC as well as the chemopreventive effects and potential molecular targets of aspirin and curcumin.

About Sabinsa

Sabinsa Corporation is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..


Sabinsa Corporation

20 Lake Drive 

East Windsor,

NJ 08520, USA

Tel: +1 732 777 1111

Fax: +1 732 777 1443

This email address is being protected from spambots. You need JavaScript enabled to view it.


Contact Presence